ABCL Stock Clocks Best Week Since February On Clinical Data Anticipation, Baker Bros Stake Boost

Trading alerts issued for AbCellera Biologics (ABCL) on NASDAQ. A covered call strategy is recommended for half of the long position. The price target is set at $20. ABCL's stock has recently spiked due to positive phase 2 data for ABCL635.

AbCellera (ABCL) reported Q2 2026 revenue of $4.1M, down from $17.1M YoY, with a net loss of $55.4M. The company advanced its pipeline, including ABCL635, which met primary endpoints in a Phase 2 study, and announced collaborations with Jazz and Vertex Pharmaceuticals, receiving upfront payments totaling $112M. ABCL ended the quarter with $675M in liquidity. Shares are up 16.78% to $12.40.

AbCellera Biologics' stock rose 14.85% to $12.19, a 52-week high, driven by positive Phase 2 trial results for its menopause drug ABCL635 and bullish analyst price target increases. The company's market value reached $3.4 billion, with analysts raising targets to $25. Despite strong gains, the stock is considered overvalued by some metrics. AbCellera also secured collaborations with Vertex and Jazz Pharmaceuticals, bringing in $100 million in upfront payments. The company reported growing revenu

AbCellera Biologics (NASDAQ:ABCL) shares rose about 64% week over week after phase 2 results for ABCL635, a treatment for hot flashes in menopausal women. In 92 postmenopausal patients, hot flash episodes fell 83% versus 33% with placebo. Truist raised its price target to $30 and peak risk-adjusted sales to $1.1B.

AbCellera (ABCL) hit a 52-week high after Phase 2 results for ABCL635 showed an 83% reduction in symptom frequency versus 33% for placebo, and Jones Research raised its price target to $25. Replimune (REPL) reached a 52-week high on a $150M financing. Airbnb (ABNB) rose to a four-year high on Q2 results and a $4.69B-$4.77B Q3 outlook.

Silence Therapeutics plc launched an underwritten U.S. ADS offering of about $150m, priced at $13.50 per ADS for 12,962,963 ADS, targeting gross proceeds of about $175m. AbCellera Biologics commenced a $200m underwritten common share offering. Beyang Therapeutics raised nearly $30m Series A, and Remepy closed a $36m Series A to fund Phase III Hybridopa.